• Date

  • Content Type

  • Reset

White Paper

Cell & Gene Therapy: Maximizing Commercialization Potential

How to Navigate the Less Obvious Barriers to Brining Advanced & Highly Targeted Treatments to


Next-Generation Approaches To Statistical Significance


By Christian K Schneider

The panel considered the potential for supplementary data sets – such as pharmacodynamic read-outs, histological


Trends in clinical development of tissue-engineered products in the EU


By Dr. Zaklina Buljovcic

While gene therapies are currently on the rise, few tissue-engineered products (TEPs) are being developed.


Science and Tech Innovation Drive Promise of Therapeutic Cancer Vaccines


By Daina Vanags, Cori Gorman & Christian K Schneider

Advances in immunotherapy treatments, starting ..

We are now Cencora PharmaLex 

PharmaLex is now part of Cencora, a leading global healthcare company with a foundation in pharmaceutical distribution. In 2024 and beyond PharmaLex and all the companies in PharmaLex family will begin a journey to becoming Cencora as well. Cencora brings the companies and services together under one new name. The name will change, but the level of attention and service you receive remains the same.  

Know more